Cancer Prevention Pharmaceuticals Revenue, Growth & Competitor Profile

DBA CANCER PREVENTION PHARMACEUTIC

Company Profile & Annual Report for Cancer Prevention Pharmaceuticals

Access the complete profile.

Cancer Prevention Pharmaceuticals Fast Facts

Revenue	$1 - $10 million    See Exact Annual Revenue
Employees	10 - 100Exact Company Size
Primary Industry	325411 Medicinal & Botanical Manufacturing
Additional NAICS Codes	325412 Pharmaceutical Preparation Manufacturing 812 Personal & Laundry Services
Address	1760 E River Rd Ste 250 Tucson, AZ 85718

Note: Revenues for privately held companies are statistical evaluations.


Cancer Prevention Pharmaceuticals's Annual Report & Profile shows critical firmographic facts:

• What is the company's size? (Annual sales and employees)
  • Cancer Prevention Pharmaceuticals's annual revenues are $1 - $10 million (see exact revenue data)
• What industry is the company in?
  • Cancer Prevention Pharmaceuticals is classified as operating in the Medicinal & Botanical Manufacturing industry, NAICS Code 325411.

Cancer Prevention Pharmaceuticals Annual Revenue and Growth Rate

Cancer Prevention Pharmaceuticals	Revenue Est. ($ Million)	Growth Rate (%)	# Employees
2023	$1 - $10 million Details in Premium Report
2022
2021
2020
2019

1-Year Growth Rate: 3-Year Growth Rate (CAGR):

Note: Cancer Prevention Pharmaceuticals's revenues are gauged from an analysis of company filings.

Cancer Prevention Pharmaceuticals's Income Statement (based on Industry Averages)

Cancer Prevention Pharmaceuticals P&L	$ Millions
Revenue (Sales)
Cost of Goods Sold
Gross Profit
Operating Expenses
Advertising
Salaries and wages
Other Operating Expenses
Total Operating Expenses
Operating Income
EBITDA
EBIT (Earnings Before Interest and Taxes)
Net Profit

Investor Activity

Cancer Prevention Pharmaceuticals has actively raised capital from investors. These investors may include private investors, venture capital firms, or other investment vehicles.

Date	Investors	Percent Raised	Target Size
January 29, 2021	6	13%	$3 MM
Complete list of funding rounds and total amounts in the Company Report

Trademark Applications

Trademark applications show the products and services that Cancer Prevention Pharmaceuticals is developing and marketing. Cancer Prevention Pharmaceuticals doesn't have any recent trademark applications, indicating Cancer Prevention Pharmaceuticals is focusing on its existing business rather than expanding into new products and markets. Trademarks may include brand names, product names, logos and slogans.

Trademark

Date

FLYNPOVI Pharmaceutical preparations for the treatment or prevention of cancer, adenocarcinomas, oncological disorders and diseases, neurological disorders and diseases, respiratory disorders and diseases, dermatological disorders and diseases, pulmonary disorders and diseases, degenerative disorders and diseases, immunological disorders and diseases, infectious disorders and diseases, cardiovascular disorders and diseases, duodenal diseases and disorders, colonic diseases and disorders, rectal diseases and disorders, urological disorders and diseases, gastrointestinal disorders and diseases, and hepatobiliary disorders and diseases; Pharmaceutical preparations to minimize the occurrence, progression, or recurrence of polyps and tumors; Pharmaceutical preparations for use in the treatment of Familial Adenomatous Polyposis and precancerous conditions; Pharmaceutical preparations for use in the prevention and treatment of cancer, precancerous conditions, tumors, polyps, adenomas, inflammation, genetic diseases and disorders, oncological diseases and disorders, and duodenal disease

03/09/2021

See all trademarks and details in the Full Report.

Market Share of Cancer Prevention Pharmaceuticals's Largest Competitors

A competitive analysis shows these companies are in the same general field as Cancer Prevention Pharmaceuticals, even though they may not compete head-to-head. These are the largest companies by revenue. However, they may not have the largest market share in this industry if they have diversified into other business lines. The "Competition" section of a business plan or investment memorandum would start by analyzing the information about these companies. Competitive advantage comes from offering better pricing or superior products/service.

Company	Headquarters	Revenue ($ MM)
XYMOGEN	Orlando, FL	100
AVANTI NUTRITIONAL LABORATORIES	Miami Lakes, FL	37
NUTRITION FORMULATORS	Miramar, FL	36
RTPR	Cabot, AR	33
INTEGRATED BOTANICS	Fort Worth, TX	29
COSMAX NBT USA	Garland, TX	29
CJB INDUSTRIES	Valdosta, GA	28
ALTERNATIVE LABORATORIES	Naples, FL	28
S&B PHARMA	Azusa, CA	28

Nearby Competitors

These companies are similar in business line and location to Cancer Prevention Pharmaceuticals. While some companies compete with neighboring businesses for customers, other companies may compete to attract skilled employees.

Company	Headquarters	Revenue ($ MM)
RAMPART BIOSCIENCE	Tucson, AZ	100
HJ3 COMPOSITE TECHNOLOGIES	Tucson, AZ	69
PENSAR OTRA VEZ	Tucson, AZ	45
CANCER PREVENTION PHARMACEUTICALS	Tucson, AZ	18
HARDY INSULATION	Tucson, AZ	13
TUCSON RUBBERIZED COATINGS	Tucson, AZ	6
DESERT POLYMERS	Tuson, AZ	3
AMPCERA	Tucson, AZ	3

Future Competition: Cancer Prevention Pharmaceuticals's Fastest Growing Competitors

These companies are in the same general field as Cancer Prevention Pharmaceuticals and are rapidly expanding. Companies may grow organically or through acquisition. In some cases apparently high growth rates may be caused by data that weren't available in previous years.

Company	Revenue ($ MM)